The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | Recent updates on pelabresib for myelofibrosis
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, talks on the use of the potentially disease-modifying bromodomain inhibitor, pelabresib, for the treatment of myelofibrosis. Dr Bose sheds light on the ongoing MANIFEST (NCT02158858) and MANIFEST-2 (NCT04603495) trials, in which the combination of pelabresib and the JAK inhibitor ruxolitinib are currently under investigation, as well as commenting on the use of pelabresib in different settings. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.
